GrifolsMEX:GRFP N 82 EV-to-FCF is 26.38 as of Jun. 30, 2026, which is 44% below its 10-year median of 46.94. GuruFocus rates MEX:GRFP N with a GF Score™ of 82/100 and a GF Value™ of MXN154.07. The stock has 6 warning signs investors should review. Among 558 Drug Manufacturers companies, Grifols ranks worse than 58.78% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Grifols's Enterprise Value is MXN334,997 Mil.
Grifols's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was MXN12,697 Mil. Therefore, Grifols's EV-to-FCF for today is 26.38.
The historical rank and industry rank for Grifols's EV-to-FCF or its related term are showing as below:
MEX:GRFP N'
s EV-to-FCF Range Over the Past 10 Years
Min: 25.81 Med: 46.94 Max: 193.53
Current: 28.17
During the past 13 years, the highest EV-to-FCF of Grifols was 193.53. The lowest was 25.81. And the median was 46.94.
MEX:GRFP N's EV-to-FCF is ranked worse than 58.78% of 558
companies
in the Drug Manufacturers industry
Industry Median: 20.045
vs MEX:GRFP N: 28.17
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
As of today (2026-06-30), Grifols's stock price is MXN126.63.
Grifols's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was MXN13.035. Therefore, Grifols's PE Ratio (TTM) for today is 9.71.
Grifols (MEX:GRFP N) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Grifols's share price for today is MXN126.63.
Grifols's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN13.035.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Grifols EV-to-FCF Related Terms
Grifols EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Grifols's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:GRFP N vs LLY, JNJ, ABBV: EV-to-FCF Comparison
For the Drug Manufacturers - General subindustry, Grifols's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Grifols EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Grifols's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Grifols's EV-to-FCF falls into.
Grifols's current Enterprise Value is MXN334,997 Mil.
Grifols's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN12,697 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Grifols (MEX:GRFP N) has a EV-to-FCF of 26.38 as of Jun. 30, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Grifols and its competitors. This is 44% below median its historical median of 46.94. Over the past decade, Grifols' EV-to-FCF has ranged from 25.81 to 193.53. According to the industry distribution chart, Grifols ranks #328 out of 558 companies in the Drug Manufacturers industry, placing it in the top 58.8%.
Is Grifols' EV-to-FCF too high?
Grifols' current EV-to-FCF of 26.38 is 44% below median its 10-year median of 46.94. Over the past 10 years, this metric has ranged from a low of 25.81 to a high of 193.53. The Drug Manufacturers industry median EV-to-FCF is 20.05. Grifols' value of 26.38 is 31.6% above this industry median. Based on the distribution chart, Grifols ranks #328 out of 558 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Grifols has a GF Score™ of 82/100, reflecting its overall financial health beyond just this single metric.
How does Grifols' EV-to-FCF compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Grifols ranks #328 out of 558 companies for EV-to-FCF. This places Grifols in the lower half of its industry. The industry median EV-to-FCF is 20.05. Grifols' value of 26.38 is 31.6% above this benchmark. Historically, Grifols' own EV-to-FCF has ranged from 25.81 to 193.53 over the past decade. While the company's 10-year median is 46.94 vs. the industry median of 20.05, Grifols has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.05, based on 558 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Grifols's current EV-to-FCF of 26.38 is 31.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Grifols and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Grifols's current EV-to-FCF is 26.38, which is 44% below median its own 10-year median of 46.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Grifols stock overvalued right now?
Grifols (MEX:GRFP N) has a current EV-to-FCF of 26.38. The stock's GF Value™ is MXN154.07, compared to a current price of MXN126.63 — trading 17.8% below its estimated fair value. The current EV-to-FCF is 26.38, which is 44% below median its 10-year median of 46.94 and 31.6% above the Drug Manufacturers industry median of 20.05. Grifols' overall GF Score™ is 82/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Grifols (MEX:GRFP N), the current EV-to-FCF is 26.38 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Grifols (MEX:GRFP N) Overvalued in 2026?
Based on GuruFocus' analysis, Grifols stock appears to be undervalued.
The current stock price of MXN126.63 is trading 17.8% below its estimated GF Value™ of MXN154.07.
Key valuation signals for MEX:GRFP N:
EV-to-FCF: 26.38 (44% below median its 10-year median of 46.94)
GF Value™: MXN154.07 vs. price of MXN126.63 (17.8% below fair value)
Industry Position: 31.6% above the Drug Manufacturers median (#328 of 558)
No single metric tells the full story. See the MEX:GRFP N stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Grifols SA is a healthcare company engaged in activities related to plasma-derived products and diagnostic solutions. The group has four reportable segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma segment focuses on products derived from human plasma for therapeutic use, while the Diagnostic segment includes the marketing of diagnostic testing equipment and reagents. The Bio Supplies segment covers biological products for non-therapeutic use and plasma sales to third parties, and the Others segment includes manufacturing services, research activities, and complementary pharmaceutical products.
82GF Score
Get the complete analysis for MEX:GRFP N
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:GRFP N has been successfully added to your 
